Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF307.50
-CHF5.00(-1.41%)
At close: 4:00 PM EST
CHF307.50
-CHF5.00(-1.41%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume2.70K
Average Volume (3M)17.31K
Market Cap
CHF4.97B
Enterprise ValueCHF4.81B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)16.3
Beta0.68
Next Earnings
Nov 18, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF342.00Price Target Upside11.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.51
Revenue Forecast (FY)CHF710.34M
Bulls Say, Bears Say
Bulls Say
Large, Diversified Delivery Systems PipelineA deep, diversified project funnel with a ~70% hit rate and 120+ likely conversions over 2–5 years materially raises the probability of sustained, recurring production contracts. This drives durable B2B revenue visibility as partnered therapies move from development into long lifecycle manufacturing.
High EBIT Margins And Proven ProfitabilitySustained EBIT margins above 30% in the core business demonstrate structural cost advantage and pricing power in device design/manufacturing. High margins support reinvestment and the company’s mid‑term margin targets, underpinning durable earnings power even with cyclical top-line swings.
Robust Operating Cash Generation And Solid Balance SheetStrong operating cash flow and a high equity ratio provide financial headroom to fund capex, customer co‑financing, and strategic initiatives. Moderate leverage (net debt/EBITDA ~0.8) coupled with rising equity supports resilience to execution risk and capacity investments over the medium term.
Bears Say
Persistently Negative Free Cash Flow HistoryDespite strong operating cash flow, multi‑year negative free cash flow reflects heavy investment and working‑capital absorption. Ongoing negative FCF constrains self‑funding of growth, raises reliance on debt/equity actions, and limits flexibility for dividends or buybacks until capex roll‑off.
Latest-year Revenue ContractionA recent group revenue drop signals near‑term top‑line volatility despite Delivery Systems growth; divestitures and phased‑out contract manufacturing reduce the revenue base. Prolonged or repeated declines could erode operating leverage and complicate achievement of mid‑term sales targets.
Large Capex & Ramp‑up/stranded Cost RiskA substantial growth capex program and site moves create execution and timing risk: empty shop floors, ramp‑up inefficiencies and stranded costs can depress near‑term margins and cash flow. Delays or lower-than-expected capacity utilisation would lengthen the payback on heavy investments.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF4.97B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 18, 2026 which is in 140 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 0.67%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF342.00
▲(11.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---